Ron H J Mathijssen
Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia.
Agema B, Buck S, Viskil M, Isebia K, de Neijs M, Sassen S, Koch B, Jörger M, de Wit R, Koolen S, Mathijssen R. Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia. Eur Urol Oncol 2023
02.11.2023Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia.
02.11.2023Eur Urol Oncol 2023
Agema Bram C, Buck Stefan A J, Viskil Mano, Isebia Khrystany T, de Neijs Micha J, Sassen Sebastiaan D T, Koch Birgit C P, Jörger Markus, de Wit Ronald, Koolen Stijn L W, Mathijssen Ron H J
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
Omlin A, Cathomas R, von Amsberg G, Reuter C, Feyerabend S, Loidl W, Boegemann M, Lorch A, Heidenreich A, Tsaur I, Larcher-Senn J, Buck S, Mathijssen R, Jaehde U, Gillessen S, Jörger M. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2023; 29:1887-1893.
15.05.2023Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
15.05.2023Clin Cancer Res 2023; 29:1887-1893
Omlin Aurelius, Cathomas Richard, von Amsberg Gunhild, Reuter Christoph, Feyerabend Susan, Loidl Wolfgang, Boegemann Martin, Lorch Anja, Heidenreich Axel, Tsaur Igor, Larcher-Senn Julian, Buck Stefan A J, Mathijssen Ron H J, Jaehde Ulrich, Gillessen Silke, Jörger Markus
Precision Dosing of Targeted Therapies Is Ready for Prime Time
Groenland S, Verheijen R, Jörger M, Mathijssen R, Sparreboom A, Beijnen J, Beumer J, Steeghs N, Huitema A. Precision Dosing of Targeted Therapies Is Ready for Prime Time. Clin Cancer Res 2021; 27:6644-6652.
21.09.2021Precision Dosing of Targeted Therapies Is Ready for Prime Time
21.09.2021Clin Cancer Res 2021; 27:6644-6652
Groenland Stefanie L, Verheijen Remy B, Jörger Markus, Mathijssen Ron H J, Sparreboom Alex, Beijnen Jos H, Beumer Jan H, Steeghs Neeltje, Huitema Alwin D R
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
Hurkmans D, Mathijssen R, Aerts J, van der Veldt A, Schreurs M, van der Leest C, Koch B, Debets R, Jörger M, Wijkhuijs A, Basak E, Putter L, de Joode K, Sassen S, Koolen S. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. J Immunother Cancer 2021; 9
01.01.2021Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
01.01.2021J Immunother Cancer 2021; 9
Hurkmans Daan P, Mathijssen Ron H J, Aerts Joachim G J V, van der Veldt Astrid A M, Schreurs Marco W J, van der Leest Cor H, Koch Birgit C P, Debets Reno, Jörger Markus, Wijkhuijs Annemarie J M, Basak Edwin A, Putter Lisanne, de Joode Karlijn, Sassen Sebastiaan D T, Koolen Stijn L W
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
Mueller-Schoell A, Schwab M, Zgheib N, Tfayli A, Chowbay B, Chen S, Eccles D, Copson E, Mathijssen R, Koolen S, Neven P, Jörger M, Huisinga W, Brauch H, Michelet R, Mürdter T, Schroth W, Klopp-Schulze L, Kloft C. Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clin Pharmacol Ther 2020; 108:661-670.
23.07.2020Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
23.07.2020Clin Pharmacol Ther 2020; 108:661-670
Mueller-Schoell Anna, Schwab Matthias, Zgheib Nathalie K, Tfayli Arafat, Chowbay Balram, Chen Sylvia, Eccles Diana, Copson Ellen, Mathijssen Ron H J, Koolen Stijn L W, Neven Patrick, Jörger Markus, Huisinga Wilhelm, Brauch Hiltrud, Michelet Robin, Mürdter Thomas, Schroth Werner, Klopp-Schulze Lena, Kloft Charlotte
Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen
Klopp-Schulze L, Mueller-Schoell A, Neven P, Koolen S, Mathijssen R, Jörger M, Kloft C. Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. Front Pharmacol 2020; 11:283.
31.03.2020Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen
31.03.2020Front Pharmacol 2020; 11:283
Klopp-Schulze Lena, Mueller-Schoell Anna, Neven Patrick, Koolen Stijn L W, Mathijssen Ron H J, Jörger Markus, Kloft Charlotte
Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
Crombag M, Koolen S, Wijngaard S, Jörger M, Dorlo T, van Erp N, Mathijssen R, Beijnen J, Huitema A. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?. Pharm Res 2019; 36:163.
15.10.2019Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
15.10.2019Pharm Res 2019; 36:163
Crombag Marie-Rose B S, Koolen Stijn L W, Wijngaard Sophie, Jörger Markus, Dorlo Thomas P C, van Erp Nielka P, Mathijssen Ron H J, Beijnen Jos H, Huitema Alwin D R
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Hurkmans D, Mathijssen R, Aerts J, van der Leest C, van der Veldt A, Odink A, Jörger M, Debets R, Hoop E, Bins S, Wijkhuijs A, Schreurs M, Mercieca D, van Dijk T, Basak E, Koolen S. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer 2019; 7:192.
19.07.2019A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
19.07.2019J Immunother Cancer 2019; 7:192
Hurkmans Daan P, Mathijssen Ron H J, Aerts Joachim G J V, van der Leest Cor H, van der Veldt Astrid A M, Odink Arlette, Jörger Markus, Debets Reno, Hoop Esther Oomen-de, Bins Sander, Wijkhuijs Annemarie J M, Schreurs Marco W J, Mercieca Darlene, van Dijk Tanja, Basak Edwin A, Koolen Stijn L W
Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study
Crombag M, Beijnen J, Mathijssen R, van Erp N, Dorlo T, Schellens J, Jörger M, Wijngaard S, Koolen S, de Vries Schultink A, Huitema A. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. Pharm Res 2019; 36:33.
07.01.2019Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study
07.01.2019Pharm Res 2019; 36:33
Crombag Marie-Rose B S, Beijnen Jos H, Mathijssen Ron H J, van Erp Nielka P, Dorlo Thomas P C, Schellens Jan H M, Jörger Markus, Wijngaard Sophie, Koolen Stijn L W, de Vries Schultink Aurelia H M, Huitema Alwin D R
Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
Kraff S, Nieuweboer A, Mathijssen R, Baty F, de Graan A, van Schaik R, Jaehde U, Jörger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother Pharmacol 2015
12.03.2015Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
12.03.2015Cancer Chemother Pharmacol 2015
Kraff Stefanie, Nieuweboer Annemieke J M, Mathijssen Ron H J, Baty Florent, de Graan Anne-Joy, van Schaik Ron H N, Jaehde Ulrich, Jörger Markus